MedPath

AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR

AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR

Approved
DIN Number

02478404

Drug Class

Human

Market Date

Mar 18, 2020

Company
HC

auro pharma inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02478404
AIG Number0352327001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification08:18.08.16
Health Canada Classification

ACTIVE INGREDIENTS (3)

EFAVIRENZActive
Strength: 600 MG
Monograph: EFAVIRENZ
EMTRICITABINEActive
Strength: 200 MG
Monograph: EMTRICITABINE
TENOFOVIR DISOPROXIL FUMARATEActive
Strength: 300 MG
Monograph: TENOFOVIR DISOPROXIL FUMARATE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.